Andrey Zarur, GreenLight Biosciences CEO
August 10, 2021 07:20 AM EDTUpdated 03:33 PM
Financing

Vir­tu­al­ly un­known mR­NA up­start rides SPAC to Nas­daq with a $1.5B val­u­a­tion as RA-backed neu­ro play­er prices IPO

Max Gelman

Senior Editor

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Just a few days af­ter EQRx

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

In his first ma­jor pol­i­cy roll­out, Vinay Prasad looks to chal­lenge ex­ist­ing 'dog­ma' on Covid vac­cines

Up­dat­ed: FDA ad­comm splits votes on Genen­tech and J&J can­cer drugs

Makary, Prasad spell out FDA ground rules for fu­ture Covid vac­cine ap­provals

RFK Jr. spars with sen­a­tors over re­search cuts, HHS bud­get plan

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times